HAL Allergy BV - Product Pipeline Review - 2015
Summary
Global Markets Directs, HAL Allergy BV - Product Pipeline Review - 2015, provides an overview of the HAL Allergy BVs pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of HAL Allergy BVs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of HAL Allergy BV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of HAL Allergy BVs human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the HAL Allergy BVs pipeline products
Reasons to buy
- Evaluate HAL Allergy BVs strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of HAL Allergy BV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the HAL Allergy BVs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of HAL Allergy BV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of HAL Allergy BV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of HAL Allergy BV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
HAL Allergy BV Snapshot 5
HAL Allergy BV Overview 5
Key Information 5
Key Facts 5
HAL Allergy BV - Research and Development Overview 6
Key Therapeutic Areas 6
HAL Allergy BV - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
HAL Allergy BV - Pipeline Products Glance 10
HAL Allergy BV - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
HAL Allergy BV - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
HAL Allergy BV - Drug Profiles 13
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Allergen for Peanut Allergy 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
HAL Allergy BV - Pipeline Analysis 18
HAL Allergy BV - Pipeline Products by Route of Administration 18
HAL Allergy BV - Pipeline Products by Molecule Type 19
HAL Allergy BV - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 21
Disclaimer 22
List Of Tables
HAL Allergy BV, Key Information 5
HAL Allergy BV, Key Facts 5
HAL Allergy BV - Pipeline by Indication, 2015 7
HAL Allergy BV - Pipeline by Stage of Development, 2015 8
HAL Allergy BV - Monotherapy Products in Pipeline, 2015 9
HAL Allergy BV - Phase III, 2015 10
HAL Allergy BV - Phase II, 2015 11
HAL Allergy BV - Phase I, 2015 12
HAL Allergy BV - Pipeline by Route of Administration, 2015 18
HAL Allergy BV - Pipeline by Molecule Type, 2015 19
List Of Figures
HAL Allergy BV - Pipeline by Top 10 Indication, 2015 7
HAL Allergy BV - Pipeline by Stage of Development, 2015 8
HAL Allergy BV - Monotherapy Products in Pipeline, 2015 9
HAL Allergy BV - Pipeline by Top 10 Route of Administration, 2015 18
HAL Allergy BV - Pipeline by Top 10 Molecule Type, 2015 19
